.Pharmacolibrary.Drugs.ATC.B.B06AC04 .Pharmacolibrary.Drugs.ATC.B.B06AC04| name: | ConestatAlfa |
| ATC code: | B06AC04 | route: | intravenous |
| n-compartments | 1 |
Conestat alfa is a recombinant human C1 esterase inhibitor (C1-INH) used for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). It functions by replacing deficient or dysfunctional C1-INH in HAE patients to inhibit the complement system and control inflammation. Conestat alfa is approved for clinical use in Europe, but not in all countries worldwide.
Pharmacokinetic parameters are estimated for typical adult patients with hereditary angioedema based on available regulatory reviews and product information, as no peer-reviewed publication with primary PK study in humans is available.
Riedl, MA, et al., & Cicardi, M (2017). Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet (London, England) 390(10102) 1595–1602. DOI:10.1016/S0140-6736(17)31963-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28754491